Literature DB >> 25712974

A Potent Virus-Specific Antibody-Secreting Cell Response to Acute Enterovirus 71 Infection in Children.

Kuan-Ying Arthur Huang1, Jainn-Jim Lin2, Cheng-Hsun Chiu1, Shuan Yang3, Kuo-Chien Tsao3, Yhu-Chering Huang4, Tzou-Yien Lin5.   

Abstract

BACKGROUND: Enterovirus 71 (EV71) remains a leading pathogen for acute infectious diseases in children, especially in Asia. The cellular basis for establishing a virus-specific antibody response to acute EV71 infections is unclear in children.
METHODS: We studied the magnitude of virus-specific antibody-secreting B cells (ASCs) and its relationship with serological response, clinical parameters, and virological parameters among children with laboratory-confirmed EV71 infection.
RESULTS: A potent EV71 genogroup B- and virus-specific ASC response was detected in the first week of illness among genotype B5 EV71-infected children. The cross-reactive EV71-specific ASC response to genogroup C viral antigens composed about 10% of the response. The EV71-specific ASC response in children aged ≥3 years produced immunoglobulin G predominantly, but immunoglobulin M was predominant in younger children. Proliferation marker was expressed by the majority of circulating ASCs in the acute phase of EV71 infection. Virus-specific ASC responses significantly correlated with throat viral load, fever duration, and serological genogroup-specific neutralization titer.
CONCLUSIONS: The presence of a virus-specific ASC response serves an early cellular marker of an EV71-specific antibody response. Further detailed study of EV71-specific ASCs at the monoclonal level is crucial to delineate the specificity and function of antibody immunity in children.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  antibody-secreting B cells; children; enterovirus 71

Mesh:

Substances:

Year:  2015        PMID: 25712974     DOI: 10.1093/infdis/jiv094

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

Review 1.  The Antibody-Secreting Cell Response to Infection: Kinetics and Clinical Applications.

Authors:  Michael J Carter; Ruth M Mitchell; Patrick M Meyer Sauteur; Dominic F Kelly; Johannes Trück
Journal:  Front Immunol       Date:  2017-06-01       Impact factor: 7.561

2.  Risk Factors for Enterovirus A71 Seropositivity in Rural Indigenous Populations in West Malaysia.

Authors:  Nmn NikNadia; I-Ching Sam; Nasibah Khaidir; Romano Ngui; Yvonne A L Lim; Xiang Ting Goh; Seow Huey Choy; Yoke Fun Chan
Journal:  PLoS One       Date:  2016-02-11       Impact factor: 3.240

3.  Correlation of symptomatic enterovirus infection and later risk of allergic diseases via a population-based cohort study.

Authors:  Zon-Min Lee; Ying-Hsien Huang; Shu-Chen Ho; Ho-Chang Kuo
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

4.  Neutralization Mechanisms of Two Highly Potent Antibodies against Human Enterovirus 71.

Authors:  Ling Zhu; Kangwei Xu; Nan Wang; Lei Cao; Junlan Wu; Qiang Gao; Elizabeth E Fry; David I Stuart; Zihe Rao; Junzhi Wang; Xiangxi Wang
Journal:  mBio       Date:  2018-07-03       Impact factor: 7.867

5.  Structural and functional analysis of protective antibodies targeting the threefold plateau of enterovirus 71.

Authors:  Kuan-Ying A Huang; Daming Zhou; Elizabeth E Fry; Abhay Kotecha; Peng-Nien Huang; Shu-Li Yang; Kuo-Chien Tsao; Yhu-Chering Huang; Tzou-Yien Lin; Jingshan Ren; David I Stuart
Journal:  Nat Commun       Date:  2020-10-16       Impact factor: 14.919

6.  Epitope-associated and specificity-focused features of EV71-neutralizing antibody repertoires from plasmablasts of infected children.

Authors:  Kuan-Ying Arthur Huang; Mei-Feng Chen; Yhu-Chering Huang; Shin-Ru Shih; Cheng-Hsun Chiu; Jainn-Jim Lin; Jen-Ren Wang; Kuo-Chien Tsao; Tzou-Yien Lin
Journal:  Nat Commun       Date:  2017-10-02       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.